JEA BizDev Consulting, LLC®
Let’s connect
JEA BizDev Consulting, LLC®

Science. Strategy. Partnership.

Reference libraries
My cross-border dealsCross-border deal library
Start a conversation
North America · Europe · Asia

Find your next opportunity.

HomeConnecting science. Creating value.PagesServicesExpertise across the BD value chainPagesAbout JohnExperience behind the partnershipsPagesOur approachFrom strategy to signed agreementPagesOpportunitiesExplore assets for partneringPagesTrack recordPartnerships and downloadable deal summariesPagesStart a conversationDiscuss an opportunity with JohnPagesMy cross-border dealsJEA reference library on Google DriveTransactionsCross-border deal libraryJEA reference library on Google DriveTransactionsDLL3 ADCOncology · IND Filing · DLL3AssetsHER2 Biparatopic ADCOncology · Phase 3 · HER2AssetsFRα Biparatopic ADCOncology · IND Filing · FRαAssetsCYP11B2 InhibitorCardiovascular · IND Filing · CYP11B2AssetsENPP1 InhibitorCardiovascular · IND Approved · ENPP1AssetsB7-H3 ADCOncology · Phase 1 · B7-H3AssetsATM InhibitorOncology · Phase 1 · ATMAssetsKAT6 InhibitorOncology · Phase 1 · KAT6A / KAT6BAssetsEGFR-ADCOncology · Phase 3 · EGFRAssetsNovaRock × Bionyra (2026)Exclusive license agreement for NBL-023, a novel anti–IL-25 monoclonal antibody, granting worldwide rights outside Greater China.TransactionsNovaRock × LigaChemBio (2026)Global out-licensing agreement for an ADC candidate targeting a novel oncology antigen.TransactionsCSPC × Radiance Biopharma (2025)$1,240 million strategic partnership for ROR1-ADC (SYS6005).TransactionsCSPC × Cipla (2025)$1,065 million strategic partnership for an Irinotecan Liposomal Injection product.TransactionsNovaRock × LigaChemBio (2025)Two global out-licensing agreements for novel antibodies.Transactions
↑ ↓ Navigate · Enter Open · Esc Close

OUR TRACK RECORD

Relationships that create value.

Selected partnerships supported by JEA BizDev Consulting as lead business development and transaction advisor, alongside examples of cross-border transaction experience.

25+

Years in healthcare leadership

85

Partnerships executed

$25B+

Total partnership value

SELECTED DISCLOSED DEAL VALUES · 2025

Partnerships with measurable scale.

$2.305B combined headline value across 2 selected deals.

Headline transaction value, USD billions. Both bars use the same scale.

  1. CSPC × Radiance Biopharma — announcement PDF, opens in a new tab$1.240B
  2. CSPC × Cipla — announcement PDF, opens in a new tab$1.065B

CLIENT SHOWCASE

Partnerships in practice.

5 partnerships

Out-licensing2026

NovaRockBionyra

NovaRock × Bionyra

Exclusive license agreement for NBL-023, a novel anti–IL-25 monoclonal antibody, granting worldwide rights outside Greater China.

Lead business development & transaction advisor

Read announcementPDF

Out-licensing2026

NovaRockLigaChemBio

NovaRock × LigaChemBio

Global out-licensing agreement for an ADC candidate targeting a novel oncology antigen.

Lead business development & transaction advisor

Read announcementPDF

Strategic partnership2025

CSPCRadiance Biopharma

CSPC × Radiance Biopharma

$1,240 million strategic partnership for ROR1-ADC (SYS6005).

Lead business development & transaction advisor

Read announcementPDF

Strategic partnership2025

CSPCCipla

CSPC × Cipla

$1,065 million strategic partnership for an Irinotecan Liposomal Injection product.

Lead business development & transaction advisor

Read announcementPDF

Out-licensing2025

NovaRockLigaChemBio

NovaRock × LigaChemBio

Two global out-licensing agreements for novel antibodies.

Lead business development & transaction advisor

Read announcementPDF

TRANSACTION PRECEDENTS

The detail behind the deal.

Explore eight deal sheet summaries covering partnerships and cross-border transactions.

Historical summaries are provided for reference. Headline values may include contingent payments.

THE NEXT CONVERSATION COULD CHANGE EVERYTHING

Great science deserves
the right partnership.

Let’s talk about where you want to go,
and how we can help you get there.

Start a conversation